CA2500368A1 — Inhibition of src for treatment of reperfusion injury related to revascularization
Assigned to St Elizabeths Medical Center of Boston Inc · Expires 2004-04-22 · 22y expired
What this patent protects
The present invention provides methods for treating, preventing, or reducing reperfusion injury or post-pump syndrome by administering an inhibitor of vascular endothelial growth factor-mediated vascular permeability.
USPTO Abstract
The present invention provides methods for treating, preventing, or reducing reperfusion injury or post-pump syndrome by administering an inhibitor of vascular endothelial growth factor-mediated vascular permeability.
Drugs covered by this patent
- Inrebic (FEDRATINIB HYDROCHLORIDE) · Bristol-Myers Squibb
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.